Zacks: Brokerages Anticipate Enanta Pharmaceuticals Inc (ENTA) Will Announce Earnings of $0.05 Per Share
Equities research analysts predict that Enanta Pharmaceuticals Inc (NASDAQ:ENTA) will report earnings per share (EPS) of $0.05 for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Enanta Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.04) and the highest estimate coming in at $0.13. Enanta Pharmaceuticals posted earnings per share of ($0.26) during the same quarter last year, which suggests a positive year-over-year growth rate of 119.2%. The business is scheduled to announce its next earnings report on Wednesday, February 14th.
According to Zacks, analysts expect that Enanta Pharmaceuticals will report full year earnings of ($1.57) per share for the current fiscal year, with EPS estimates ranging from ($2.36) to ($0.78). Zacks Investment Research’s earnings per share calculations are an average based on a survey of analysts that cover Enanta Pharmaceuticals.
Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its earnings results on Monday, November 20th. The biotechnology company reported $1.86 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $2.13 by ($0.27). Enanta Pharmaceuticals had a return on equity of 6.46% and a net margin of 17.23%. The business had revenue of $75.93 million for the quarter, compared to analysts’ expectations of $73.80 million. During the same period last year, the business earned ($0.09) EPS. The company’s revenue for the quarter was up 491.3% on a year-over-year basis.
Enanta Pharmaceuticals (ENTA) opened at $53.98 on Thursday. Enanta Pharmaceuticals has a fifty-two week low of $25.92 and a fifty-two week high of $54.83. The stock has a market cap of $1,030.00, a price-to-earnings ratio of 54.76 and a beta of 0.64.
A number of hedge funds have recently added to or reduced their stakes in the stock. GSA Capital Partners LLP grew its position in Enanta Pharmaceuticals by 143.2% during the third quarter. GSA Capital Partners LLP now owns 19,700 shares of the biotechnology company’s stock valued at $922,000 after buying an additional 11,600 shares during the period. Dimensional Fund Advisors LP grew its position in Enanta Pharmaceuticals by 1.4% during the third quarter. Dimensional Fund Advisors LP now owns 562,394 shares of the biotechnology company’s stock valued at $26,320,000 after buying an additional 7,617 shares during the period. Schwab Charles Investment Management Inc. grew its position in Enanta Pharmaceuticals by 5.2% during the third quarter. Schwab Charles Investment Management Inc. now owns 56,419 shares of the biotechnology company’s stock valued at $2,641,000 after buying an additional 2,803 shares during the period. Campbell & CO Investment Adviser LLC acquired a new stake in Enanta Pharmaceuticals during the third quarter valued at $220,000. Finally, Wells Fargo & Company MN grew its position in Enanta Pharmaceuticals by 36.7% during the third quarter. Wells Fargo & Company MN now owns 18,197 shares of the biotechnology company’s stock valued at $852,000 after buying an additional 4,886 shares during the period. Institutional investors own 66.97% of the company’s stock.
About Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.